替诺福韦酯挽救治疗HBV DNA聚合酶区204位点突变的经治慢性乙型肝炎患者疗效及安全性分析

doi:10.3969/j.issn.1672-5069.2019.03.010

摘要/Abstract

摘要： 目的探讨应用替诺福韦酯（TDF）挽救治疗HBV DNA聚合酶区204位点突变的经治的慢性乙型肝炎（CHB）患者的疗效及安全性。方法 2013年8月~2015年12月我院诊治的CHB患者87例,纳入患者均为曾接受拉米夫定（LAM）或阿德福韦酯（ADV）治疗6个月以上,血清HBV DNA阴转后又复阳,且经检测出现rtl204v耐药者,43例接受恩替卡韦（ETV）治疗,另44例接受TDF治疗,观察疗效,并使用流式细胞仪检测外周血CD4⁺T淋巴细胞计数,常规计算内生肌酐清除率（Crcl）。结果在治疗24 w、48 w和72 w时,TDF治疗组血清HBV DNA阴转率分别为63.6%、79.6%和95.5%,显著高于ETV治疗组【分别为35.6%、55.6%和82.2%,P<0.05】,血清ALT复常率分别为84.1%、90.9%和93.2%,而ETV 治疗组则分别为65.1%（P<0.05）、83.7%和90.7%;TDF治疗组外周血CD4⁺T细胞计数分别为（481.5±232.4）/μl、（536.5±297.5）/μl和（566.5±321.6）/μl,与ETV治疗组比,无显著性差异【分别为（475.3±229.3）/μl、（565.8±255.9）/μl和（565.1±256.5）/μl,P<0.05】;Crcl分别为（101.2±40.1）ml/min、（104.3±26.8） ml/min和（98.7±21.5） ml/min,与ETV治疗组比,无显著性差异【分别为（105.2±42.6） ml/min、（102.5±30.6） ml/min和（99.6±26.8） ml/min,P<0.05】。结论 TDF和ETV挽救治疗对核苷（酸）类治疗耐药的经治CHB患者均有良好的疗效,但似乎TDF起效更快,而ETV用量较大,不应列为首选。

关键词: 慢性乙型肝炎, 替诺福韦酯, 恩替卡韦, 挽救治疗, 经治

Abstract: Objectiv To explore the efficacy and safety of tenofovir disoproxil fumarate（TDF） and entecavir （ETV） in the treatment of chronic hepatitis B （CHB） patients with viral DNA polymerase 204 site mutation infection. Methods 87 CHB patients with HBV polymerase 204 site mutation infection due to resistance to lamivudine or adefovir therapy were recruited in this study between August of 2013 and September 2015,and 44 patients received TDF and 43 received ETV treatment. The peripheral CD4⁺T lymphocyte counts were detected by FCM,and creatinine clearance （Crcl） was calculated based on serum creatinine levels. Results At the end of 24 w,48 w and 72 w treatment,serum HBV DNA loss in TDF-treated patients were 63.6%,79.6% and 95.5%,significantly higher than 35.6%,55.6% and 82.2%,respectively,in ETV-treated patients（P<0.05）,and serum ALT normalization rates were 84.1%,90.9% and 93.2%,while they were 65.1%（P<0.05）,83.7% and 90.7% in ETV-treated patients;the peripheral blood CD4⁺T cell counts were （481.5±232.4）/μl,（536.5±297.5）/μl and （566.5±321.6）/μl,no significantly different as compared to （475.3±229.3）/μl,（565.8±255.9）/μl and （565.1± 256.5）/μl in ETV-treated patients （P<0.05）;the Crcl levels were （101.2±40.1） ml/min,（104.3±26.8） ml/min and （98.7±21.5） ml/min,also without significantly different as compared to （105.2±42.6） ml/min,（102.5±30.6） ml/min and （99.6±26.8） ml/min in ETV-treated patients（P<0.05）. Conclusion TDF might be the priority option in dealing with CHB patients with HBV mutant infection for rescue therapy as it works early,convenient and safe.

Key words: Hepatitis B, Tenofovir disoproxil fumarate, Entecavir, Rescue therapy, LAM-resistant, ADV-resistant

杨蕊西, 刘茗心, 陈泠忻, 施剑, 瞿波. 替诺福韦酯挽救治疗HBV DNA聚合酶区204位点突变的经治慢性乙型肝炎患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(3): 349-352.

Yang Ruixi, Liu Mingxin, Chen Lingxi. Efficacy and safety of tenofovir disoproxil fumarate and entecavir in the treatment of chronic hepatitis B patients with viral DNA polymerase 204 site mutation infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 349-352.

参考文献

[1] Wang YQ,Wu T,Hu DQ,et al.Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein. J Lipid Res,2018,59(1):58-68.
[2] 邢文斌,郭晓楠,徐慧宁. HLA-DRB多态性与HBV感染的相关性研究. 中华实验和临床感染病杂志(电子版),2015,8(1):63-66.
[3] Li Y,Zhang Z,Shi J,et al.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. Int [J] Clin Exp Med. 2015,8(1):1205.
[4] Li Y,Li S,Duan X,et al.Interferon-stimulated gene 15 conjugation stimulates hepatitis B virus production independent of type I interferon signaling pathway in vitro. Mediat Inflamm,2016,2016(6):7417648.
[5] Ye C,Lu J,Li L.Nucleoside analogues improve the short-term prognosis of chronic hepatitis B patients when they suffered an acute-on-chronic liver failure. J Hepatol,2016,64(2):S586-S586.
[6] Takamatsu Y,Tanaka Y,Kohgo S,et al.4′-modified nucleoside analogs:potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology,2015,62(4):1024.
[7] 肖金成,李靖,陈呈世,等. 胰腺癌患者乙型肝炎病毒感染的预防介入治疗与生存率分析. 中华医院感染学杂志,2015,24(14):3249-3251.
[8] Peng CY,Hsieh TC,Hsieh TY,et al.HBV DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. J Formos Med Assoc,2015,114(4):308-313.
[9] Wang Y,Liu S,Chen YU,et al.Lamivudine-resistant rtl180m and rtm204i/v are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med,2016,11(6):2293.
[10] 贺露露,陈飞. 阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化患者血清细胞因子水平的变化. 实用肝脏病杂志,2017,20(2):234-235.
[11] Villa G,Phillips RO,Smith C,et al.Renal health after long-term exposure to tenofovir disoproxil fumarate(TDF) in HIV/HBV positive adults in Ghana. J Infect,2018,11(9):e0005968.
[12] Yasutake Y,Hattori S,et al.HIV-1 with HBV-associated q151m substitution in rt becomes highly susceptible to entecavir:structural insights into HBV-rt inhibition by entecavir. Sci Rep,2018,11(9):e0005968.
[13] Gopalan N,Chandrasekaran P.Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther,2016,13(1):34.
[14] Weinschenk L,Gollnest T,Schols D,et al.Bis(benzoyloxybenzyl)-dippro nucleoside diphosphates of anti-HIV active nucleoside analogues. Chem Med Chem,2015,10(5):891.
[15] Sivay MV,Li M,Piwowarmanning E,et al.Characterization of HIV seroconverters in a tdf/ftc prep study:hptn 067/adapt. J Acquir Immune Defic Syndr,2017,75(3):271.
[16] Svarovskaia ES,Curtis M,Zhu Y,et al.Hepatitis B virus wild-type and rtn236t populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. J Viral Hepat,2013,20(2):131-140.
[17] 潘静,陆伦根. 核苷(酸)类似物初始治疗慢性乙型肝炎患者疗效和安全性的网络Meta分析. 实用肝脏病杂志,2017,20(1):29-33.
[18] Scheiner B,Mandorfer M,Schwabl P,et al.The impact of pnpla3 rs738409 snp on liver fibrosis progression,portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS One,2015,10(11):e0143429.
[19] Audsley J,Bent S J,Littlejohn M,et al.Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. AIDS,2016,30(10):1597.
[20] Castilho JL,Shepherd BE,Koethe J,et al.CD4+/CD8+ ratio,age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS,2016,30(6):899-908.
[21] Mbugua KK,Holmes MJ,Cotton MF,et al.HIV-associated CD4+/CD8+ depletion in infancy is associated with neurometabolic reductions in the basal ganglia at age 5 years despite early antiretroviral therapy. AIDS,2016,30(9):1353.